BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26271204)

  • 1. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
    van den Berg H; Paulussen M; Le Teuff G; Judson I; Gelderblom H; Dirksen U; Brennan B; Whelan J; Ladenstein RL; Marec-Berard P; Kruseova J; Hjorth L; Kühne T; Brichard B; Wheatley K; Craft A; Juergens H; Gaspar N; Le Deley MC;
    Eur J Cancer; 2015 Nov; 51(16):2453-64. PubMed ID: 26271204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.
    Le Deley MC; Paulussen M; Lewis I; Brennan B; Ranft A; Whelan J; Le Teuff G; Michon J; Ladenstein R; Marec-Bérard P; van den Berg H; Hjorth L; Wheatley K; Judson I; Juergens H; Craft A; Oberlin O; Dirksen U
    J Clin Oncol; 2014 Aug; 32(23):2440-8. PubMed ID: 24982464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.
    Corvest V; Marec-Bérard P; Lervat C; Pacquement H; Toulmonde M; Gentet JC; Laurence V; Cleirec M; Mansuy L; Bompas E; Castex MP; Taque S; Filhon B; Tabone MD; Verité C; Entz-Werle N; Saumet L; Guimard G; Pondrom M; Chevreau C; Flandrin J; Duranteau L; Rousset-Jablonski C; Brugières L; Jimenez M; Le Deley MC; Gaspar N; Fresneau B
    Int J Cancer; 2023 Apr; 152(8):1659-1667. PubMed ID: 36250317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
    Anderton J; Moroz V; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Kaiser S; Fernández-Pinto M; Fenwick N; Evans A; Strauss S; Whelan J; Wheatley K; Brennan B
    Trials; 2020 Jan; 21(1):96. PubMed ID: 31952545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).
    Fresneau B; Hackshaw A; Hawkins DS; Paulussen M; Anderson JR; Judson I; Litière S; Dirksen U; Lewis I; van den Berg H; Gaspar N; Gelderblom H; Whelan J; Boddy AV; Wheatley K; Pignon JP; De Vathaire F; Le Deley MC; Le Teuff G
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Brennan B; Kirton L; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Fenwick N; Strauss S; Moroz V; Whelan J; Wheatley K
    Lancet; 2022 Oct; 400(10362):1513-1521. PubMed ID: 36522207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
    Dirksen U; Brennan B; Le Deley MC; Cozic N; van den Berg H; Bhadri V; Brichard B; Claude L; Craft A; Amler S; Gaspar N; Gelderblom H; Goldsby R; Gorlick R; Grier HE; Guinbretiere JM; Hauser P; Hjorth L; Janeway K; Juergens H; Judson I; Krailo M; Kruseova J; Kuehne T; Ladenstein R; Lervat C; Lessnick SL; Lewis I; Linassier C; Marec-Berard P; Marina N; Morland B; Pacquement H; Paulussen M; Randall RL; Ranft A; Le Teuff G; Wheatley K; Whelan J; Womer R; Oberlin O; Hawkins DS;
    J Clin Oncol; 2019 Dec; 37(34):3192-3202. PubMed ID: 31553693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
    Womer RB; West DC; Krailo MD; Dickman PS; Pawel BR; Grier HE; Marcus K; Sailer S; Healey JH; Dormans JP; Weiss AR
    J Clin Oncol; 2012 Nov; 30(33):4148-54. PubMed ID: 23091096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
    Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
    J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
    Granowetter L; Womer R; Devidas M; Krailo M; Wang C; Bernstein M; Marina N; Leavey P; Gebhardt M; Healey J; Shamberger RC; Goorin A; Miser J; Meyer J; Arndt CA; Sailer S; Marcus K; Perlman E; Dickman P; Grier HE
    J Clin Oncol; 2009 May; 27(15):2536-41. PubMed ID: 19349548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
    Mascarenhas L; Felgenhauer JL; Bond MC; Villaluna D; Femino JD; Laack NN; Ranganathan S; Meyer J; Womer RB; Gorlick R; Krailo MD; Marina N
    Pediatr Blood Cancer; 2016 Mar; 63(3):493-8. PubMed ID: 26579879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
    Brunetto AL; Castillo LA; Petrilli AS; Macedo CD; Boldrini E; Costa C; Almeida MT; Kirst D; Rodriguez-Galindo C; Pereira WV; Watanabe FM; Pizza M; Benites E; Morais V; Gadelha A; Nakasato A; Abujamra AL; Gregianin LJ;
    Pediatr Blood Cancer; 2015 Oct; 62(10):1747-53. PubMed ID: 25917418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
    Paioli A; Luksch R; Fagioli F; Tamburini A; Cesari M; Palmerini E; Abate ME; Marchesi E; Balladelli A; Pratelli L; Ferrari S
    J Chemother; 2014 Feb; 26(1):49-56. PubMed ID: 24091100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.
    Paulussen M; Ahrens S; Dunst J; Winkelmann W; Exner GU; Kotz R; Amann G; Dockhorn-Dworniczak B; Harms D; Müller-Weihrich S; Welte K; Kornhuber B; Janka-Schaub G; Göbel U; Treuner J; Voûte PA; Zoubek A; Gadner H; Jürgens H
    J Clin Oncol; 2001 Mar; 19(6):1818-29. PubMed ID: 11251014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience.
    Zhang J; Huang Y; Sun Y; He A; Zhou Y; Hu H; Yao Y; Shen Z
    BMC Cancer; 2019 Dec; 19(1):1168. PubMed ID: 31791278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study.
    Ferrari S; Palmerini E; Alberghini M; Staals E; Mercuri M; Barbieri E; Longhi A; Cantero L; Cesari M; Abate M; Balladelli A; Picci P; Bacci G
    Tumori; 2010; 96(2):213-8. PubMed ID: 20572576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
    Juergens C; Weston C; Lewis I; Whelan J; Paulussen M; Oberlin O; Michon J; Zoubek A; Juergens H; Craft A
    Pediatr Blood Cancer; 2006 Jul; 47(1):22-9. PubMed ID: 16572419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
    J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
    Laurence V; Pierga JY; Barthier S; Babinet A; Alapetite C; Palangié T; de Pinieux G; Anract P; Pouillart P
    Am J Clin Oncol; 2005 Jun; 28(3):301-9. PubMed ID: 15923805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study.
    Ahrens S; Hoffmann C; Jabar S; Braun-Munzinger G; Paulussen M; Dunst J; Rübe C; Winkelmann W; Heinecke A; Göbel U; Winkler K; Harms D; Treuner J; Jürgens H
    Med Pediatr Oncol; 1999 Mar; 32(3):186-95. PubMed ID: 10064186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.